A citation-based method for searching scientific literature

Yumi Yokoyama, Erin D Lew, Ruth Seelige, Elizabeth A Tindall, Colin Walsh, Patrick C Fagan, Jack Y Lee, Robin Nevarez, Joanne Oh, Kathleen D Tucker, Marissa Chen, Amy Diliberto, Heather Vaaler, Kristen M Smith, Amanda Albert, Gary Li, Jack D Bui. Cancer Res 2019
Times Cited: 42







List of co-cited articles
605 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


TAM receptors are pleiotropic inhibitors of the innate immune response.
Carla V Rothlin, Sourav Ghosh, Elina I Zuniga, Michael B A Oldstone, Greg Lemke. Cell 2007
702
50

The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.
Douglas K Graham, Deborah DeRyckere, Kurtis D Davies, H Shelton Earp. Nat Rev Cancer 2014
405
45

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.
Magdalena Paolino, Axel Choidas, Stephanie Wallner, Blanka Pranjic, Iris Uribesalgo, Stefanie Loeser, Amanda M Jamieson, Wallace Y Langdon, Fumiyo Ikeda, Juan Pablo Fededa,[...]. Nature 2014
287
35


R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
Sacha J Holland, Alison Pan, Christian Franci, Yuanming Hu, Betty Chang, Weiqun Li, Matt Duan, Allan Torneros, Jiaxin Yu, Thilo J Heckrodt,[...]. Cancer Res 2010
353
30

Diversification of TAM receptor tyrosine kinase function.
Anna Zagórska, Paqui G Través, Erin D Lew, Ian Dransfield, Greg Lemke. Nat Immunol 2014
252
30

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.
Christine Gjerdrum, Crina Tiron, Torill Høiby, Ingunn Stefansson, Hallvard Haugen, Tone Sandal, Karin Collett, Shan Li, Emmet McCormack, Bjørn Tore Gjertsen,[...]. Proc Natl Acad Sci U S A 2010
406
30

TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.
Rachel M A Linger, Amy K Keating, H Shelton Earp, Douglas K Graham. Adv Cancer Res 2008
486
28

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhenfeng Zhang, Jae Cheol Lee, Luping Lin, Victor Olivas, Valerie Au, Thomas LaFramboise, Mohamed Abdel-Rahman, Xiaoqi Wang, Alan D Levine, Jin Kyung Rho,[...]. Nat Genet 2012
859
28

MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
Alisa B Lee-Sherick, Kristen M Jacobsen, Curtis J Henry, Madeline G Huey, Rebecca E Parker, Lauren S Page, Amanda A Hill, Xiaodong Wang, Stephen V Frye, H Shelton Earp,[...]. JCI Insight 2018
38
31

Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells.
Heather M Seitz, Todd D Camenisch, Greg Lemke, H Shelton Earp, Glenn K Matsushima. J Immunol 2007
271
28

Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.
Canan Kasikara, Viralkumar Davra, David Calianese, Ke Geng, Thomas E Spires, Michael Quigley, Michael Wichroski, Ganapathy Sriram, Lucia Suarez-Lopez, Michael B Yaffe,[...]. Cancer Res 2019
50
28

T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response.
Eugenio A Carrera Silva, Pamela Y Chan, Leonel Joannas, Andrea E Errasti, Nicola Gagliani, Lidia Bosurgi, Maurice Jabbour, Anthony Perry, Faye Smith-Chakmakova, Daniel Mucida,[...]. Immunity 2013
117
26


Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation.
Wen-I Tsou, Khanh-Quynh N Nguyen, Daniel A Calarese, Scott J Garforth, Anita L Antes, Sergey V Smirnov, Steve C Almo, Raymond B Birge, Sergei V Kotenko. J Biol Chem 2014
140
26

UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.
Weihe Zhang, Deborah DeRyckere, Debra Hunter, Jing Liu, Michael A Stashko, Katherine A Minson, Christopher T Cummings, Minjung Lee, Trevor G Glaros, Dianne L Newton,[...]. J Med Chem 2014
91
26

Immunobiology of the TAM receptors.
Greg Lemke, Carla V Rothlin. Nat Rev Immunol 2008
563
26

Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.
Erin D Lew, Jennifer Oh, Patrick G Burrola, Irit Lax, Anna Zagórska, Paqui G Través, Joseph Schlessinger, Greg Lemke. Elife 2014
162
26

Biology of the TAM receptors.
Greg Lemke. Cold Spring Harb Perspect Biol 2013
331
26

An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies.
X Ye, Y Li, S Stawicki, S Couto, J Eastham-Anderson, D Kallop, R Weimer, Y Wu, L Pei. Oncogene 2010
159
23

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.
Katherine A Minson, Catherine C Smith, Deborah DeRyckere, Clara Libbrecht, Alisa B Lee-Sherick, Madeline G Huey, Elisabeth A Lasater, Gregory D Kirkpatrick, Michael A Stashko, Weihe Zhang,[...]. JCI Insight 2016
36
27

MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.
Rebecca S Cook, Kristen M Jacobsen, Anne M Wofford, Deborah DeRyckere, Jamie Stanford, Anne L Prieto, Elizabeth Redente, Melissa Sandahl, Debra M Hunter, Karen E Strunk,[...]. J Clin Invest 2013
111
23

The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases.
T N Stitt, G Conn, M Gore, C Lai, J Bruno, C Radziejewski, K Mattsson, J Fisher, D R Gies, P F Jones. Cell 1995
587
23


TAM receptor signaling in immune homeostasis.
Carla V Rothlin, Eugenio A Carrera-Silva, Lidia Bosurgi, Sourav Ghosh. Annu Rev Immunol 2015
254
23

axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase.
J P O'Bryan, R A Frye, P C Cogswell, A Neubauer, B Kitch, C Prokop, R Espinosa, M M Le Beau, H S Earp, E T Liu. Mol Cell Biol 1991
623
23

Sitravatinib potentiates immune checkpoint blockade in refractory cancer models.
Wenting Du, Huocong Huang, Noah Sorrelle, Rolf A Brekken. JCI Insight 2018
53
23

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Lauren Averett Byers, Lixia Diao, Jing Wang, Pierre Saintigny, Luc Girard, Michael Peyton, Li Shen, Youhong Fan, Uma Giri, Praveen K Tumula,[...]. Clin Cancer Res 2013
663
23

Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP.
Yi Zhou, Mingjian Fei, Gu Zhang, Wei-Ching Liang, WeiYu Lin, Yan Wu, Robert Piskol, John Ridgway, Erin McNamara, Haochu Huang,[...]. Immunity 2020
118
23

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.
Julia Boshuizen, Louise A Koopman, Oscar Krijgsman, Aida Shahrabi, Elke Gresnigt- van den Heuvel, Maarten A Ligtenberg, David W Vredevoogd, Kristel Kemper, Thomas Kuilman, Ji-Ying Song,[...]. Nat Med 2018
123
21

Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.
Sutapa Sinha, Justin Boysen, Michael Nelson, Charla Secreto, Steven L Warner, David J Bearss, Connie Lesnick, Tait D Shanafelt, Neil E Kay, Asish K Ghosh. Clin Cancer Res 2015
52
21

Phagocytosis and clearance of apoptotic cells is mediated by MER.
R S Scott, E J McMahon, S M Pop, E A Reap, R Caricchio, P L Cohen, H S Earp, G K Matsushima. Nature 2001
862
21

UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models.
Deborah DeRyckere, Alisa B Lee-Sherick, Madeline G Huey, Amanda A Hill, Jeffrey W Tyner, Kristen M Jacobsen, Lauren S Page, Gregory G Kirkpatrick, Fatma Eryildiz, Stephanie A Montgomery,[...]. Clin Cancer Res 2017
38
23

Tyro-3 family receptors are essential regulators of mammalian spermatogenesis.
Q Lu, M Gore, Q Zhang, T Camenisch, S Boast, F Casagranda, C Lai, M K Skinner, R Klein, G K Matsushima,[...]. Nature 1999
372
21

Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases.
Anouk Caraux, Qingxian Lu, Nadine Fernandez, Sylvain Riou, James P Di Santo, David H Raulet, Greg Lemke, Claude Roth. Nat Immunol 2006
102
21

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang, Keiko Tanimura, Yuta Adachi, Akihiro Nishiyama, Azusa Tanimoto, Shinji Takeuchi, Luiz H Araujo, Mariana Boroni,[...]. Nat Commun 2019
134
21

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
S Betty Yan, Victoria L Peek, Rose Ajamie, Sean G Buchanan, Jeremy R Graff, Steven A Heidler, Yu-Hua Hui, Karen L Huss, Bruce W Konicek, Jason R Manro,[...]. Invest New Drugs 2013
103
21

Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
R M A Linger, R A Cohen, C T Cummings, S Sather, J Migdall-Wilson, D H G Middleton, X Lu, A E Barón, W A Franklin, D T Merrick,[...]. Oncogene 2013
140
21

MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
Jin Kyung Rho, Yun Jung Choi, Seon Ye Kim, Tae Won Kim, Eun Kyung Choi, Seon-Joo Yoon, Bu Man Park, Eunhye Park, Jong Hwan Bae, Chang-Min Choi,[...]. Cancer Res 2014
103
19

MERTK as negative regulator of human T cell activation.
Raquel Cabezón, E Antonio Carrera-Silva, Georgina Flórez-Grau, Andrea E Errasti, Elisabeth Calderón-Gómez, Juan José Lozano, Carolina España, Elena Ricart, Julián Panés, Carla Vanina Rothlin,[...]. J Leukoc Biol 2015
60
19


An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis.
Mihalis S Kariolis, Yu Rebecca Miao, Douglas S Jones, Shiven Kapur, Irimpan I Mathews, Amato J Giaccia, Jennifer R Cochran. Nat Chem Biol 2014
92
19

Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer.
Kathleen F Ludwig, Wenting Du, Noah B Sorrelle, Katarzyna Wnuk-Lipinska, Mary Topalovski, Jason E Toombs, Victoria H Cruz, Shinichi Yabuuchi, N V Rajeshkumar, Anirban Maitra,[...]. Cancer Res 2018
84
19

Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response.
Eric Ubil, Laura Caskey, Alisha Holtzhausen, Debra Hunter, Charlotte Story, H Shelton Earp. J Clin Invest 2018
78
16

Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.
Alexis Mollard, Steven L Warner, Lee T Call, Mark L Wade, Jared J Bearss, Anupam Verma, Sunil Sharma, Hariprasad Vankayalapati, David J Bearss. ACS Med Chem Lett 2011
57
16

AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.
Samuel H Myers, Valerie G Brunton, Asier Unciti-Broceta. J Med Chem 2016
119
16

Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
Wilhem Leconet, Myriam Chentouf, Stanislas du Manoir, Clément Chevalier, Audrey Sirvent, Imade Aït-Arsa, Muriel Busson, Marta Jarlier, Nina Radosevic-Robin, Charles Theillet,[...]. Clin Cancer Res 2017
64
16

Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.
Gretchen M Schroeder, Yongmi An, Zhen-Wei Cai, Xiao-Tao Chen, Cheryl Clark, Lyndon A M Cornelius, Jun Dai, Johnni Gullo-Brown, Ashok Gupta, Benjamin Henley,[...]. J Med Chem 2009
221
16

The Emerging Role of TYRO3 as a Therapeutic Target in Cancer.
Sherri K Smart, Eleana Vasileiadi, Xiaodong Wang, Deborah DeRyckere, Douglas K Graham. Cancers (Basel) 2018
37
18

The mer receptor tyrosine kinase: expression and function suggest a role in innate immunity.
Edward M Behrens, Paul Gadue, Shun-you Gong, Stacey Garrett, Paul L Stein, Philip L Cohen. Eur J Immunol 2003
86
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.